Digital pathology firm Gestalt, and Primaa, a MedTech pioneer specialising in AI-based dermatopathology solutions, have announced a strategic partnership.
The new collaboration brings Primaa's AI technology for skin cancer diagnosis directly into Gestalt's PathFlow platform. Together, they aim to create seamless workflows for pathologists while upholding the highest levels of diagnostic precision and patient safety.
Gestalt's PathFlow is known for its versatility, supporting primary diagnoses, education, resident training, and research workflows. By integrating Primaa's advanced AI algorithms, the platform now empowers pathologists with enhanced tools for detecting and quantifying tumour biomarkers in skin tissues.
This integration allows pathologists to utilise AI-driven algorithms that detect critical biomarkers in skin lesions. Through the combined offering can automatically identify lesion types - including melanoma, squamous cell carcinoma, and basal cell carcinoma - and provides detailed measurements of lesion dimensions and margins. The solution also detects automatically all perineural invasions and all mitosis objects in the melanoma. Additionally, the system prioritises high-risk cases for immediate review, ensuring timely and accurate diagnosis.
"Partnering with Primaa to integrate its skin AI technology into PathFlow underscores our dedication to providing pathologists with state-of-the-art tools," said Lisa-Jean Clifford, COO and Chief Strategy Officer of Gestalt. "This partnership represents a pivotal advancement in enhancing workflow efficiency and delivering superior patient care related to skin cancer."
Fanny Sockeel, CEO at Primaa, added: "Our collaboration with Gestalt, a leader in digital pathology, marks a significant step toward integrating AI seamlessly into pathologists' workflows. Together, we aim to empower pathologists with cutting-edge technology that supports faster, more precise diagnoses - ultimately improving patient outcomes."
Gestalt's PathFlow follows the LDT process in the US. It is under CE-IVD marking for use in Europe.